Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

Key Takeaways Incyte shares sank Monday after the drugmaker released the latest data from a clinical trial.The drug, ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

As previously reported, Guggenheim downgraded Incyte (INCY) to Neutral from Buy and removed the firm’s previous $92 price target after the ...

Results from the Phase III STOP-HS1 and STOP-HS2 trials show that povorcitinib (Incyte), an oral JAK1 inhibitor, successfully met the primary endpoint in treating moderate to severe hidradenitis ...

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

The conference call will also be webcast live and can be accessed at investor.incyte.com. Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical ...